David Shook sold $6,350 of LYEL
Chief Medical Officer at Lyell Immunopharma, Inc.. 500 shares at an average of $12.70, traded Sep 10, 2026, filed Sep 10, 2026.
Score components
- +15RoleOfficer
- 0Trade size$6k at market
- 0Share of holdings soldSold 2.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001959742-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | SOpen-market sale Common Stock | -500 | $12.70 | $6,350 | 20,423 | 32 d ago |
Related signals
Other insiders at Lyell Immunopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | LYELbuy Lyell Immunopharma, Inc. | Otis W Brawley director | $20k 35,640 shares | - | |
| 31Weak | LYELbuy Lyell Immunopharma, Inc. | Richard Klausner director | $95k 158,000 shares | +23% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.